BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-34. [PMID: 20664471 DOI: 10.1097/MPA.0b013e3181ebaffd] [Cited by in Crossref: 184] [Cited by in F6Publishing: 189] [Article Influence: 14.2] [Reference Citation Analysis]
Number Citing Articles
1 Prieto TG, Baldavira CM, Machado-Rugolo J, Olivieri EHR, da Silva ECA, Ab' Saber AM, Takagaki TY, Capelozzi VL. Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms. Genes (Basel) 2022;13. [PMID: 36553576 DOI: 10.3390/genes13122309] [Reference Citation Analysis]
2 Arman T, Nelson PS. Endocrine and paracrine characteristics of neuroendocrine prostate cancer. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1012005] [Reference Citation Analysis]
3 Gubbi S, Vijayvergia N, Yu JQ, Klubo-Gwiezdzinska J, Koch CA. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Horm Metab Res 2022;54:795-812. [PMID: 35878617 DOI: 10.1055/a-1908-7790] [Reference Citation Analysis]
4 Huang K, Lan Z, Chen W, Zhang J, Wang J, Zhu H, Xu B, Zhang L, Lu T, Guo Y, Wen Z. Hepatectomy and pneumectomy combined with targeted therapy for primary hepatic neuroendocrine carcinoma: Case report and review of the literature. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.920276] [Reference Citation Analysis]
5 Andriani J, Budipramana VS, Sadikin C. Diagnostic problem of Primary Hepatic Neuroendocrine Tumor in 18-year-old woman: A case report. International Journal of Surgery Case Reports 2022;95:107224. [DOI: 10.1016/j.ijscr.2022.107224] [Reference Citation Analysis]
6 Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, Bali U, Moraitis AG. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Front Endocrinol (Lausanne) 2021;12:793262. [PMID: 35058882 DOI: 10.3389/fendo.2021.793262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Patel KR, Nahar A, Elhassan YS, Shetty S, Smith S, Vickrage S, Kemp‐blake J, Palani R, Geh I, Venkataraman H, Shah T, Ayuk J. The effects of somatostatin analogues on glycaemia in the treatment of neuroendocrine tumours. J Neuroendocrinology. [DOI: 10.1111/jne.13064] [Reference Citation Analysis]
8 Seki Y, Sakata H, Uekusa T, Momose H, Yoneyama S, Hidemura A, Tajima Y, Suzuki H, Ishimaru M. Primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy: a case report. Surg Case Rep 2021;7:236. [PMID: 34727269 DOI: 10.1186/s40792-021-01315-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Christ E, Antwi K, Fani M, Wild D. Innovative imaging of insulinoma: the end of sampling? A review. Endocr Relat Cancer 2020;27:R79-92. [PMID: 31951592 DOI: 10.1530/ERC-19-0476] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
10 Ravikumar R, Avasthi S, Avasthi D. Flushing: A Diagnostic Dilemma. Cureus 2021;13:e15515. [PMID: 34277159 DOI: 10.7759/cureus.15515] [Reference Citation Analysis]
11 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, Quelle DE. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Sci Rep 2021;11:10252. [PMID: 33986468 DOI: 10.1038/s41598-021-89866-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Dulin PA, Makanin MA, Krainyukov PE, Simonenko AV, Korolev AV. Synchronous gastric tumors: carcinoid tumor and adenocarcinoma. jour 2021;98:619-623. [DOI: 10.30629/0023-2149-2020-98-8-619-623] [Reference Citation Analysis]
14 Sung MJ, Chung MJ. Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor. Korean J Pancreas Biliary Tract 2021;26:24-32. [DOI: 10.15279/kpba.2021.26.1.24] [Reference Citation Analysis]
15 Grimaldi F, Vescini F, Kara E. Treatment of NET-Related Symptoms. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_7] [Reference Citation Analysis]
16 Markovich AA, Lyubimova NV, Kovalenko EI, Bagrova SG, Besova NS, Emelyanova GS, Gorbunova VA, Artamonova EV. Importance of biochemical markers in routine oncological practice (according to materials of clinical recommendations). Medicinskij alfavit 2020. [DOI: 10.33667/2078-5631-2020-8-19-24] [Reference Citation Analysis]
17 Pettersson O, Fröss-Baron K, Crona J, Sundin A. Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. Front Oncol 2020;10:193. [PMID: 32154181 DOI: 10.3389/fonc.2020.00193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
18 Heymann JJ, Siddiqui MT. Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review. Acta Cytol 2020;64:103-23. [PMID: 30970350 DOI: 10.1159/000497153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Taggart MW, Foo WC, Lee SM. Tumors of the Gastrointestinal System Including the Pancreas. Oncological Surgical Pathology 2020. [DOI: 10.1007/978-3-319-96681-6_12] [Reference Citation Analysis]
20 党 智. Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System. ACM 2020;10:2444-2450. [DOI: 10.12677/acm.2020.1011369] [Reference Citation Analysis]
21 Blot K, Duchateau L, Lescrauwaet B, Liyanage N, Ray D, Mirakhur B, Vinik AI. A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial. Patient Relat Outcome Meas 2019;10:335-43. [PMID: 31754316 DOI: 10.2147/PROM.S219982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Zekri J, Rasool HJ, Meliti A, Rasool J. Neuroendocrine tumor of the kidney: Diagnostic challenge and successful therapy. Urol Ann 2019;11:435-8. [PMID: 31649468 DOI: 10.4103/UA.UA_169_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
24 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Sandblom V, Ståhl I, Hansson C, Olofsson Bagge R, Forssell-Aronsson E. Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion - A preclinical simulation of a novel treatment strategy. Surg Oncol 2019;29:148-56. [PMID: 31196481 DOI: 10.1016/j.suronc.2019.05.002] [Reference Citation Analysis]
26 Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J Jr, Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019;11:E586. [PMID: 31027285 DOI: 10.3390/cancers11040586] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
27 Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest 2019;129:1641-53. [PMID: 30721156 DOI: 10.1172/JCI123049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
28 Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther 2019;12:1717-28. [PMID: 30881026 DOI: 10.2147/OTT.S182259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun 2019;10:278. [PMID: 30655535 DOI: 10.1038/s41467-018-08133-6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 93] [Article Influence: 19.8] [Reference Citation Analysis]
30 Dillhoff ME, Ellison EC. Zollinger-Ellison Syndrome. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00060-1] [Reference Citation Analysis]
31 Laing E, Kiss N, Michael M, Gough K, Krishnasamy M. Investigating Nutrition-Related Complications and Quality of Life in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Protocol for a Mixed-Methods Prospective Study. JMIR Res Protoc 2018;7:e11228. [PMID: 30567691 DOI: 10.2196/11228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, Nervi B, Sánchez C, Galindo H, Ibañez C, Peña J, Balmaceda C, Madrid J, Briones J, Torres J, Nilo F, Guarda FJ, Quintana JC, Orellana P, Mondaca S, Acevedo F, Vicentini D, Cordova-Delgado M, Owen GI, Garrido M. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer 2019;10:3-10. [PMID: 30465145 DOI: 10.1007/s12672-018-0354-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
33 Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 2018;8:16863. [PMID: 30442902 DOI: 10.1038/s41598-018-35340-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
34 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
35 Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord 2017;18:381-91. [PMID: 28871510 DOI: 10.1007/s11154-017-9428-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
36 Polenta V, Slater EP, Kann PH, Albers MB, Manoharan J, Ramaswamy A, Mahnken AH, Bartsch DK. Preoperative Imaging Overestimates the Tumor Size in Pancreatic Neuroendocrine Neoplasms Associated with Multiple Endocrine Neoplasia Type 1. World J Surg 2018;42:1440-7. [PMID: 29075857 DOI: 10.1007/s00268-017-4317-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
37 Tseng CM, Cheng TY, Chen TB, Tien YW, Chen CC, Lin JT, Wang HP. Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol Lett 2018;15:8951-8. [PMID: 29805630 DOI: 10.3892/ol.2018.8472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, Jiménez-Fonseca P, Sevilla MI, Capdevila J. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol 2018;20:1522-8. [PMID: 29766455 DOI: 10.1007/s12094-018-1881-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
39 Borre M, Dam GA, Knudsen AW, Grønbaek H. Nutritional status and nutritional risk in patients with neuroendocrine tumors. Scand J Gastroenterol 2018;53:284-92. [PMID: 29373941 DOI: 10.1080/00365521.2018.1430848] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
40 Doi R. Rare Neuroendocrine Tumors of the Pancreas. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch135] [Reference Citation Analysis]
41 Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, Bollmann C, Kann PH, Bartsch DK. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1. World J Surg 2017;41:1521-7. [PMID: 28138732 DOI: 10.1007/s00268-017-3907-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
42 Samiee-rad F, Zangivand AA, Soleimanitadi K, Kalhor M. Primary typical pulmonary carcinoid tumor: an incidental finding. Comp Clin Pathol 2018;27:261-264. [DOI: 10.1007/s00580-017-2595-z] [Reference Citation Analysis]
43 Bouquot M, Gaujoux S, Cauchy F, Birnbaum D, Dokmak S, Levy P, Soubrane O, Sauvanet A. Pancreatectomy for pancreatic incidentaloma: What are the risks? Pancreatology 2018;18:114-21. [PMID: 29146108 DOI: 10.1016/j.pan.2017.11.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
44 Yu R. Neuroendocrine Tumors. Reference Module in Biomedical Sciences 2018. [DOI: 10.1016/b978-0-12-801238-3.00012-x] [Reference Citation Analysis]
45 Maistrenko NA, Romashchenko PN, Orlova RV, Lysanyuk MV. Possibilities of treating patients with generalized neuroendocrine tumors. Onkol Z im P A Gercena 2018;7:16. [DOI: 10.17116/onkolog20187216-25] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Ferone D, Nazzari E, Grillo F, Sciallero S, Morbelli S, De Cian F, Cittadini G, Albertelli M, Edoardo G. Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. Atlas of Thyroid and Neuroendocrine Tumor Markers 2018. [DOI: 10.1007/978-3-319-62506-5_14] [Reference Citation Analysis]
47 Seregni E, Lorenzoni A. Circulating Markers in Neuroendocrine Tumors. Atlas of Thyroid and Neuroendocrine Tumor Markers 2018. [DOI: 10.1007/978-3-319-62506-5_15] [Reference Citation Analysis]
48 La Rosa S, Bongiovanni M, Uccella S. Pathology of Neuroendocrine Neoplasms: Morphological, Immunophenotypical, and Circulating Molecular Markers. Atlas of Thyroid and Neuroendocrine Tumor Markers 2018. [DOI: 10.1007/978-3-319-62506-5_2] [Reference Citation Analysis]
49 Lieske B. Carcinoid Tumours of the Gastrointestinal System: Neuroendocrine Tumours of the Hindgut. Evidence-Based Endocrine Surgery 2018. [DOI: 10.1007/978-981-10-1124-5_37] [Reference Citation Analysis]
50 Manfrin E, Sonzogni A, Scarpa A, Pelosi G. Classification of Abdominal Neuroendocrine Tumors. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_2] [Reference Citation Analysis]
51 Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 2018;472:341-9. [PMID: 29134440 DOI: 10.1007/s00428-017-2258-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 13.8] [Reference Citation Analysis]
52 Pavel M, Unger N, Borbath I, Ricci S, Hwang TL, Brechenmacher T, Park J, Herbst F, Beaumont JL, Bechter O. Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. Target Oncol. 2016;11:667-675. [PMID: 27193465 DOI: 10.1007/s11523-016-0440-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
53 Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther 2017;10:5013-30. [PMID: 29081664 DOI: 10.2147/OTT.S142087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
54 Broder MS, Chang E, Reddy SR, Neary MP. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Pancreas 2017;46:891-7. [PMID: 28697129 DOI: 10.1097/MPA.0000000000000872] [Reference Citation Analysis]
55 Hart EA, Meijs TA, Meijer RCA, Dreijerink KM, Tesselaar ME, de Groot CA, Valk GD, Chamuleau SAJ. Carcinoid heart disease: a guide for screening and timing of surgical intervention. Neth Heart J 2017;25:471-8. [PMID: 28631210 DOI: 10.1007/s12471-017-1011-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
56 Aluri V, Dillon JS. Biochemical Testing in Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2017;46:669-77. [PMID: 28760232 DOI: 10.1016/j.ecl.2017.04.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
57 Wang H, Liang C, Wu C, Chiu Y, Chou Y, Wu K, Huang C, Chuah S, Tai W, Lu L. Metachronous duodenal neuroendocrine neoplasms after endoscopic mucosal resection. Advances in Digestive Medicine 2017;4:71-75. [DOI: 10.1002/aid2.12071] [Reference Citation Analysis]
58 Wolin EM, Leyden J, Goldstein G, Kolarova T, Hollander R, Warner RRP. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States. Pancreas 2017;46:639-47. [PMID: 28328615 DOI: 10.1097/MPA.0000000000000818] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
59 Popa E, Schnoll-sussman F, Jesudian A, Nandakumar G, Shah MA. Uncommon Cancers of the Stomach. Textbook of Uncommon Cancer 2017. [DOI: 10.1002/9781119196235.ch27] [Reference Citation Analysis]
60 Wong K, Chondrogiannis S, Fuster D, Ruiz C, Marzola M, Giammarile F, Colletti P, Rubello D. Additional value of hybrid SPECT/CT systems in neuroendocrine tumors, adrenal tumors, pheochromocytomas and paragangliomas. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2017;36:103-9. [DOI: 10.1016/j.remnie.2016.09.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Sandblom V, Ståhl I, Olofsson Bagge R, Forssell-Aronsson E. Evaluation of two intraoperative gamma detectors for assessment of 177Lu activity concentration in vivo. EJNMMI Phys 2017;4:3. [PMID: 28070731 DOI: 10.1186/s40658-016-0168-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
62 Piciu D. Neuroendocrine Tumors (NET). Nuclear Endocrinology 2017. [DOI: 10.1007/978-3-319-56582-8_10] [Reference Citation Analysis]
63 Shi Y, Qian ZR, Zhang S, Li W, Masugi Y, Li T, Chan JA, Yang J, Da Silva A, Gu M, Liu L, Hamada T, Kosumi K, Dutton T, Brais LK, Nishihara R, Fuchs CS, Ogino S, Kulke MH. Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index. Pancreas 2017;46:1347-53. [PMID: 28991877 DOI: 10.1097/MPA.0000000000000944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
64 Eriksson J, Garmo H, Hellman P, Ihre-Lundgren C. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol 2017;24:1214-20. [PMID: 27904972 DOI: 10.1245/s10434-016-5703-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
65 Phan AT, Dave B. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med 2016;5:2953-64. [PMID: 27539383 DOI: 10.1002/cam4.742] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
66 Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534-545. [PMID: 25962092 DOI: 10.4158/ep14464.dsc] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
67 Herrera MF, Åkerström G, Angelos P, Grant CS, Hoff AO, Pantoja JP, Pérez-Johnston R, Sahani DV, Wong RJ, Randolph G. AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas. Endocr Pract 2015;21:546-53. [PMID: 25962093 DOI: 10.4158/EP14465.DSC] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
68 Cho JH, Ryu JK, Song SY, Hwang JH, Lee DK, Woo SM, Joo YE, Jeong S, Lee SO, Park BK, Cheon YK, Han J, Kim TN, Lee JK, Moon SH, Kim H, Park ET, Hwang JC, Kim TH, Jeon TJ, Cho CM, Choi HS, Lee WJ. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016;45:941-6. [PMID: 26765964 DOI: 10.1097/MPA.0000000000000586] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
69 Ragab Shalaby AM, Kazuei H, Koichi H, Naguib S, Al-Menawei LA. Assessment of intracranial metastases from neuroendocrine tumors/carcinoma. J Neurosci Rural Pract 2016;7:435-9. [PMID: 27365963 DOI: 10.4103/0976-3147.182779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
70 Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf) 2016;85:400-7. [PMID: 27256431 DOI: 10.1111/cen.13119] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
71 Wong KK, Gandhi A, Viglianti BL, Fig LM, Rubello D, Gross MD. Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography. World J Radiol 2016; 8(6): 635-655 [PMID: 27358692 DOI: 10.4329/wjr.v8.i6.635] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
72 Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Öberg K, Leyden J. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol 2017;3:43-53. [PMID: 28717741 DOI: 10.1200/JGO.2015.002980] [Cited by in Crossref: 68] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
73 Qureshi SA, Burch N, Druce M, Hattersley JG, Khan S, Gopalakrishnan K, Darby C, Wong JL, Davies L, Fletcher S, Shatwell W, Sothi S, Randeva HS, Dimitriadis GK, Weickert MO. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: A cross-sectional study. BMJ Open. 2016;6:e010765. [PMID: 27147385 DOI: 10.1136/bmjopen-2015-010765] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
74 Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol 2016; 7(1): 117-124 [PMID: 26909234 DOI: 10.4291/wjgp.v7.i1.117] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
75 Pérez-Pevida B, Idoate MÁ, Fernández-Landázuri S, Varo N, Escalada J. Hypoglycemic Syndrome without Hyperinsulinemia. A Diagnostic Challenge. Endocr Pathol 2016;27:50-4. [PMID: 26801953 DOI: 10.1007/s12022-016-9415-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
76 Akimoto J, Fukuhara H, Suda T, Nagai K, Ichikawa M, Fukami S, Kohno M, Matsubayashi J, Nagao T. Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain. BMC Cancer 2016;16:36. [PMID: 26801624 DOI: 10.1186/s12885-015-1999-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
77 Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med. 2016;57:872-878. [PMID: 26769864 DOI: 10.2967/jnumed.115.165803] [Cited by in Crossref: 139] [Cited by in F6Publishing: 147] [Article Influence: 19.9] [Reference Citation Analysis]
78 Thakker RV. Multiple Endocrine Neoplasia Type 1. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00148-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Seydafkan S, Coppola D. Neuroendocrine Tumor Classification Systems: Grading. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_1] [Reference Citation Analysis]
80 Yu R. Neuroendocrine Tumor Syndromes. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00150-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
81 Hameed U, Cukier M, Hallet J, Law CHL, Rowsell C, Singh S. Neuroendocrine Tumors (GastroEnteroPancreatic). Surgical Oncology Manual 2016. [DOI: 10.1007/978-3-319-26276-5_16] [Reference Citation Analysis]
82 Carolan PJ, Chung DC. Neuroendocrine Tumors of the Pancreas. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch88] [Reference Citation Analysis]
83 Isidori AM, Sbardella E, Zatelli MC, Boschetti M, Vitale G, Colao A, Pivonello R; ABC Study Group. Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. J Clin Endocrinol Metab 2015;100:3231-44. [PMID: 26158607 DOI: 10.1210/JC.2015-1589] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 9.5] [Reference Citation Analysis]
84 Antonakis PT, Ashrafian H, Martinez-Isla A. Pancreatic insulinomas: Laparoscopic management. World J Gastrointest Endosc 2015; 7(16): 1197-1207 [PMID: 26566426 DOI: 10.4253/wjge.v7.i16.1197] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
85 Simon EP, Freije CA, Farber BA, Lalazar G, Darcy DG, Honeyman JN, Chiaroni-Clarke R, Dill BD, Molina H, Bhanot UK, La Quaglia MP, Rosenberg BR, Simon SM. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A 2015;112:E5916-25. [PMID: 26489647 DOI: 10.1073/pnas.1424894112] [Cited by in Crossref: 79] [Cited by in F6Publishing: 86] [Article Influence: 9.9] [Reference Citation Analysis]
86 Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer 2015;22:933-40. [PMID: 26373569 DOI: 10.1530/ERC-15-0314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
87 Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075-5086. [PMID: 26366058 DOI: 10.2147/dddt.s84177] [Cited by in Crossref: 133] [Cited by in F6Publishing: 141] [Article Influence: 16.6] [Reference Citation Analysis]
88 Guimarães M, Rodrigues P, Pereira SS, Nora M, Gonçalves G, Albrechtsen NW, Hartmann B, Holst JJ, Monteiro MP. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol Diabetes Metab Case Rep 2015;2015:150049. [PMID: 26266036 DOI: 10.1530/EDM-15-0049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
89 Karavias D, Habeos I, Maroulis I, Kalogeropoulou C, Tsamandas A, Chaveles I, Karavias D. Giant malignant insulinoma. Ann Surg Treat Res 2015;88:289-93. [PMID: 25960993 DOI: 10.4174/astr.2015.88.5.289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
90 Yang X, Yang Y, Li Z, Cheng C, Yang T, Wang C, Liu L, Liu S. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015;10:e0124884. [PMID: 25894842 DOI: 10.1371/journal.pone.0124884] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
91 Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol 2015; 21(8): 2450-2459 [PMID: 25741154 DOI: 10.3748/wjg.v21.i8.2450] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
92 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192. [PMID: 24699927 DOI: 10.1007/s12022-014-9313-z] [Cited by in Crossref: 112] [Cited by in F6Publishing: 120] [Article Influence: 14.0] [Reference Citation Analysis]
93 Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
94 Hameed S, Wills M, Rockall A. Cross-Sectional Imaging of Neuroendocrine Tumours. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_8] [Reference Citation Analysis]
95 Williamson JML. Somatostatinoma. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_16] [Reference Citation Analysis]
96 Orlewska E, Bednarczuk T, Kaminski G, Kos-Kudla B; LanroNET study group*. LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis. Contemp Oncol (Pozn) 2014;18:442-7. [PMID: 25784845 DOI: 10.5114/wo.2014.47908] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
97 Landry CS, Cavaness K, Celinski S, Preskitt J. Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors. Gland Surg 2014;3:215-8. [PMID: 25493250 DOI: 10.3978/j.issn.2227-684X.2014.10.01] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
98 Cui MH, Branch CA, Cahill SM, Quinn TJ, Adem A, Libutti SK, Yuan Z. In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med 2015;74:1221-6. [PMID: 25392979 DOI: 10.1002/mrm.25529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
99 Calissendorff J, Maret E, Sundin A, Falhammar H. Ileal neuroendocrine tumors and heart: not only valvular consequences. Endocrine 2015;48:743-55. [PMID: 25319177 DOI: 10.1007/s12020-014-0446-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
100 Hagen J, Muniz VP, Falls KC, Reed SM, Taghiyev AF, Quelle FW, Gourronc FA, Klingelhutz AJ, Major HJ, Askeland RW, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR, Darbro BW, Quelle DE. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. Cancer Res 2014;74:6661-70. [PMID: 25273089 DOI: 10.1158/0008-5472.CAN-13-3742] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
101 Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64. [PMID: 25099181 DOI: 10.1186/1472-6823-14-64] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
102 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
103 Schipper HM, Jay CA, Abrams GM. Sex Hormone, Pituitary, Parathyroid, and Adrenal Disorders and the Nervous System. Aminoff's Neurology and General Medicine 2014. [DOI: 10.1016/b978-0-12-407710-2.00020-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Wong KK, Kandathil A, Rubello D, Gross MD. Functional Oncological Imaging of the Endocrine System. Functional Imaging in Oncology 2014. [DOI: 10.1007/978-3-642-40582-2_28] [Reference Citation Analysis]
105 Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45:1483-1486. [PMID: 24185511 DOI: 10.1038/ng.2821] [Cited by in Crossref: 221] [Cited by in F6Publishing: 236] [Article Influence: 22.1] [Reference Citation Analysis]
106 Krivko AA, Mel'nichenko GA, Kuznetsov NS, Troshina EA, Dedov II. Modern technologies for diagnostics and treatment of insulinoma. Probl Endokrinol (Mosk) 2013;59:36-41. [DOI: 10.14341/probl201359536-41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, Wong C, Chadwick C, George K, Keevil B, Adaway J, Ardill JE, Anthoney A, Hofmann U, Poston GJ, Cuthbertson DJ. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One 2013;8:e73679. [PMID: 24069222 DOI: 10.1371/journal.pone.0073679] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
108 Cummins M, Pavlakis N. The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol 2013;5:286-300. [PMID: 23997829 DOI: 10.1177/1758834013501016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
109 Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013;40:1770-80. [PMID: 23873003 DOI: 10.1007/s00259-013-2482-z] [Cited by in Crossref: 129] [Cited by in F6Publishing: 136] [Article Influence: 12.9] [Reference Citation Analysis]
110 Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One 2013;8:e61538. [PMID: 23620762 DOI: 10.1371/journal.pone.0061538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
111 Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer. 2013;108:1838-1845. [PMID: 23579216 DOI: 10.1038/bjc.2013.156] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 9.3] [Reference Citation Analysis]
112 Strosberg JR, Fisher GA, Benson AB, Malin JL, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM; GEPNET Treatment Consensus Panel. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 2013;42:397-404. [PMID: 23211372 DOI: 10.1097/MPA.0b013e31826d3a17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
113 Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20:187-196. [PMID: 23319495 DOI: 10.1530/erc-12-0340] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 8.0] [Reference Citation Analysis]
114 Bourcier ME, Vinik AI. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas 2013;42:348-52. [PMID: 23407483 DOI: 10.1097/MPA.0b013e31825c53fa] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
115 Gedde-Dahl M, Thiis-Evensen E, Tjølsen AM, Mordal KS, Vatn M, Bergestuen DS. Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors. Endocr Connect 2013;2:50-4. [PMID: 23781318 DOI: 10.1530/EC-12-0077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
116 Pisegna JR. Neuroendocrine Tumors. Molecular Pathology Library 2013. [DOI: 10.1007/978-1-4614-6015-2_12] [Reference Citation Analysis]
117 Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:705-17. [PMID: 23582914 DOI: 10.1016/j.bpg.2013.01.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
118 Gastrointestinal Pathology Study Group of Korean Society of Pathologists. Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat. 2012;44:157-165. [PMID: 23091441 DOI: 10.4143/crt.2012.44.3.157] [Cited by in Crossref: 136] [Cited by in F6Publishing: 151] [Article Influence: 12.4] [Reference Citation Analysis]
119 Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17:747-755. [PMID: 22628056 DOI: 10.1634/theoncologist.2011-0458] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
120 Cerwenka H. Neuroendocrine liver metastases: Contributions of endoscopy and surgery to primary tumor search. World J Gastroenterol 2012; 18(10): 1009-1014 [PMID: 22416174 DOI: 10.3748/wjg.v18.i10.1009] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
121 Popa E, Schnoll‐sussman F, Jesudian A, Nandakumar G, Shah MA. Uncommon Cancers of the Stomach. Textbook of Uncommon Cancer 2012. [DOI: 10.1002/9781118464557.ch28] [Reference Citation Analysis]
122 Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80-87. [PMID: 22350660 DOI: 10.1007/s12020-012-9631-1] [Cited by in Crossref: 182] [Cited by in F6Publishing: 191] [Article Influence: 16.5] [Reference Citation Analysis]
123 Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Göke B, Auernhammer CJ. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 2012;4:141-55. [PMID: 24213232 DOI: 10.3390/cancers4010141] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
124 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R;  Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. [PMID: 22261919 DOI: 10.1159/000335591] [Cited by in Crossref: 374] [Cited by in F6Publishing: 408] [Article Influence: 34.0] [Reference Citation Analysis]
125 Anlauf M, Gerlach P, Schott M, Raffel A, Krausch M, Knoefel WT, Pavel M, Klöppel G. [Pathology of neuroendocrine neoplasms]. Chirurg 2011;82:567-73. [PMID: 21487814 DOI: 10.1007/s00104-011-2067-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
126 Ihler F, Vetter EV, Pan J, Kammerer R, Debey-Pascher S, Schultze JL, Zimmermann W, Enders G. Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen. PLoS One 2012;7:e29846. [PMID: 22253802 DOI: 10.1371/journal.pone.0029846] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
127 Koshimizu H, Omori H, Funase Y, Tsukada Y, Tauchi K, Furukawa T, Oguchi K, Tanaka M, Higuchi K, Aizawa T. Pancreatic nonfunctioning neuroendocrine tumor with the main pancreatic duct obstruction presenting as excessive hyperglycemia: a case report and review of the literature. Pancreas 2012;41:160-3. [PMID: 22173831 DOI: 10.1097/MPA.0b013e318221c4c1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
128 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB; UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 387] [Cited by in F6Publishing: 379] [Article Influence: 35.2] [Reference Citation Analysis]
129 Piciu D. Neuroendocrine Tumors (NET). Nuclear Endocrinology 2012. [DOI: 10.1007/978-3-642-25014-9_10] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Toumpanakis C. Molecular profile and diagnosis. Advances in Neuroendocrine Tumor Management 2011. [DOI: 10.2217/ebo.11.84] [Reference Citation Analysis]
131 Guerrero Vázquez R, Oliva Rodríguez R, Cuenca Cuenca JI, Sánchez Alberdi F, Navarro González E. Glucagonoma maligno como causa infrecuente de diabetes de inicio. Endocrinología y Nutrición 2011;58:199-201. [DOI: 10.1016/j.endonu.2010.10.013] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Rodriguez A, Canto MI, Makary MA. Endoscopic localization and tattooing of a proinsulinoma for minimally invasive resection. Pancreas 2011;40:474-7. [PMID: 21412118 DOI: 10.1097/MPA.0b013e318205e926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
133 Guerrero Vázquez R, Oliva Rodríguez R, Cuenca Cuenca JI, Sánchez Alberdi F, Navarro González E. Malignant glucagonoma: An uncommon cause of new onset diabetes. Endocrinología y Nutrición (English Edition) 2011;58:199-201. [DOI: 10.1016/s2173-5093(11)70045-9] [Reference Citation Analysis]